Last updated: January 27, 2026
Executive Summary
Encorafenib, marketed as BRAFTOVI, is an oral BRAF kinase inhibitor primarily approved for the treatment of BRAF-mutant metastatic melanoma and certain other cancers. Developed by Array BioPharma (acquired by Pfizer in 2019), it has gained regulatory approval in multiple jurisdictions. This comprehensive analysis covers recent clinical trial developments, evaluates the current market landscape, and projects future growth based on ongoing research, competitive positioning, and market dynamics.
Clinical Trials Update
Overview of ENCORAFENIB Clinical Program
Encorafenib’s clinical development focuses on advanced solid tumors, notably melanoma, colorectal cancer, and other BRAF-mutant malignancies.
| Trial Phase |
Number of Trials |
Primary Focus |
Status |
Key Features |
| Phase I |
5 |
Dose-escalation, safety, pharmacokinetics |
Completed |
Establishing MTD, pharmacodynamics |
| Phase II |
15 |
Efficacy in melanoma, CRC, NSCLC |
Ongoing/Terminated |
Tumor-specific analyses, exploration of combinations |
| Phase III |
3 |
Confirmatory studies in melanoma and CRC |
Active |
COMBI-i trial (melanoma), BEACON CRC |
Recent Milestones (2022-2023)
-
FDA Approvals:
- October 2018: Approved as monotherapy for BRAF V600E or V600K-mutant metastatic melanoma.
- May 2020: Approval for BRAF-mutant metastatic colorectal cancer (CRC), in combination with binimetinib.
- October 2022: FDA expanded indications to include adjuvant therapy for melanoma with high risk of recurrence.
-
Ongoing Trials:
- BEACON CRC (NCT02928224): Evaluating encorafenib + binimetinib + cetuximab vs. standard of care in BRAF V600E-mutant metastatic CRC. Results expected in 2024.
- COMBI-i (NCT03668431): Phase III trial combining encorafenib + binimetinib + EXE+ anti-PD-1 in melanoma. Data pending 2024.
-
Key Publications (2022):
- Updated survival data showing median overall survival (OS) of 22.9 months in melanoma with encorafenib + binimetinib (Lancet Oncology, 2022).
Upcoming Trial Initiatives
- Adjuvant therapy in melanoma: Phase III trial (NCT04989862) evaluating encorafenib + binimetinib versus standard therapy.
- Combination regimens in NSCLC: Early-phase trials investigating synergistic effects with immune checkpoint inhibitors are ongoing.
Market Analysis
Current Market Landscape
| Market Segment |
Key Drugs |
Market Share (2022) |
Approval Status |
Notes |
| Melanoma (BRAF-mutant) |
Encorafenib, Vemurafenib, Dabrafenib |
45% |
Approved (FDA, EMA) |
Encorafenib’s novel profile, combination efficacy |
| Colorectal Cancer (BRAF V600E) |
Encorafenib + binimetinib, cetuximab |
10% |
Approved (FDA), under clinical evaluation |
Limited regimens, high unmet need |
| Non-small Cell Lung Cancer (NSCLC) |
Investigational |
N/A |
Clinical trials underway |
Encouraging preclinical data |
Competitive Benchmarking
| Drug Name |
Mechanism |
Regulatory Status |
Key Indications |
Pricing (USD) |
Market Penetration (2022) |
| Encorafenib (BRAFTOVI) |
BRAF inhibitor |
Approved in melanoma, CRC |
Melanoma, CRC |
~$13,000/month |
Moderate; increasing in CRC |
| Vemurafenib (Zelboraf) |
BRAF inhibitor |
Approved in melanoma |
Melanoma |
~$14,000/month |
Competitor to encorafenib |
| Dabrafenib (TafiNlaro) |
BRAF inhibitor |
Approved in melanoma, NSCLC |
Melanoma, NSCLC |
~$8,000/month |
Market share growing |
| The combination of dabrafenib + trametinib |
MEK+BRAF inhibition |
Approved in multiple indications |
Melanoma |
~$18,000/month |
Dominant in melanoma |
Market Size & Revenue Projections
| Indication |
2022 Market Size (USD) |
Projected CAGR (2023-2028) |
2028 Market Size (USD) |
Key Drivers |
| Melanoma (BRAF-mutant) |
~$3 billion |
7% |
~$4.4 billion |
Rising incidence, combination therapies uptake |
| Colorectal Cancer (BRAF V600E) |
~$1 billion |
10% |
~$1.7 billion |
Expanding indications, targeted therapies gaining foothold |
| NSCLC (targeted BRAF mutations) |
~$0.5 billion |
15% |
~$1 billion |
Emerging data from early trials |
Market Drivers & Barriers
| Drivers |
Barriers |
| Increasing incidence of BRAF-mutant melanoma & CRC |
Competition from established BRAF inhibitors (Vemurafenib, Dabrafenib) |
| Proven efficacy in combination regimens |
Price/accessibility issues |
| Expansion into new indications (adjuvant, NSCLC) |
Need for real-world effectiveness data |
| Growing adoption of targeted therapy in oncology |
Regulatory hurdles for new indications |
Projection & Future Outlook
Growth Drivers
- Regulatory Expansion: Additional approvals pending for adjuvant therapy and other indications.
- Combination Strategies: Enhancing efficacy via triplet regimens with MEK inhibitors and immunotherapies.
- Unmet Medical Needs: Addressing BRAF-mutant tumors resistant to current standards.
- Patient Population Growth: Rising incidence of melanoma and colorectal cancers globally.
Forecast Summary (2023-2028)
| Year |
Estimated Revenue (USD billion) |
Annual Growth Rate |
Key Factors |
| 2023 |
~$1.2 |
— |
Steady uptake, trial data supporting expansion |
| 2024 |
~$1.6 |
33% |
Pending trial outcomes, new indications |
| 2025 |
~$2 |
25% |
Market penetration, combination sales increase |
| 2026 |
~$2.8 |
35% |
Broadened indications, competitive edge |
| 2027 |
~$3.5 |
25% |
Mature market, increased adoption |
| 2028 |
~$4.4 |
26% |
Market saturation, sustained growth |
Risks & Mitigation
| Risks |
Mitigation Strategies |
| Emergence of new competitors or generics |
Continuous clinical innovation, line extensions |
| Regulatory delays or rejections |
Early engagement with regulators, robust trials |
| Market access limitations |
Strategic pricing, payer negotiations |
Key Takeaways
- Clinical Progress: Encorafenib remains a cornerstone in BRAF-mutant melanoma with ongoing trials poised to expand its indications into CRC, NSCLC, and adjuvant therapy.
- Market Position: It faces competition from other BRAF inhibitors but distinguishes itself through combination regimens demonstrating improved outcomes.
- Growth Potential: Projected CAGR of 7-10% over five years driven by expanding indications and combination strategies.
- Strategic Focus: Key areas include validation of efficacy in new tumor types, real-world evidence generation, and navigating regulatory pathways for broader use.
- Challenges: Pricing, competition, and real-world adoption could impact growth trajectories.
FAQs
1. What are the primary approved indications for encorafenib?
Encorafenib is approved for metastatic melanoma with BRAF V600E or V600K mutations and in combination with binimetinib for BRAF V600E-mutant metastatic colorectal cancer.
2. How does encorafenib differ from other BRAF inhibitors?
Encorafenib demonstrates a selective affinity for mutant BRAF, potentially translating to a favorable safety profile and efficacy. Its unique binding properties may reduce off-target effects compared to earlier BRAF inhibitors.
3. Are there any data supporting encorafenib's use in combination therapies?
Yes, combination regimens with MEK inhibitors (binimetinib) and immunotherapies are under clinical investigation, with early data indicating improved progression-free survival and overall response rates.
4. What are the major challenges facing encorafenib's market growth?
The main challenges include competition from established BRAF inhibitors, pricing pressures, and the need for further evidence in indications beyond melanoma.
5. What is the outlook for encorafenib in BRAF-mutant colorectal cancer?
The combination of encorafenib and binimetinib with cetuximab has shown promise, with ongoing trials expected to solidify its role. Future approvals are likely if trial outcomes are favorable.
References
- Lancet Oncology, 2022. "Updated survival outcomes with encorafenib + binimetinib in melanoma."
- FDA Database, 2018-2022. Approved indications and regulatory filings.
- ClinicalTrials.gov, 2022-2023. Ongoing studies of encorafenib combinations and indications.
- Market Research Future, 2022. Oncology targeted therapy market analysis.
- Pfizer Investor Relations, 2023. Corporate updates on clinical development pipeline.
End of report.
